Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential.

Blaschke M, Cameron S, Emami K, Blumberg J, Wegner U, Nischwitz M, Ramadori G.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):83-5. No abstract available.

PMID:
21176739
2.
3.

Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.

Wattanatorn W, McLeod HL, Macklon F, Reid M, Kendle KE, Cassidy J.

Pharmacotherapy. 1997 Sep-Oct;17(5):881-6.

PMID:
9324177
4.

Altered plasma kinetics of 5-FU at high dosage in rat and man.

Schwartz PM, Turek PJ, Hyde CM, Cadman EC, Handschumacher RE.

Cancer Treat Rep. 1985 Jan;69(1):133-6.

PMID:
3967255
5.
6.

5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients.

Müller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blochl-Daum B.

Cancer Res. 1997 Jul 1;57(13):2598-601.

7.

Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.

Finch RE, Bending MR, Lant AF.

Br J Clin Pharmacol. 1979 Jun;7(6):613-7.

8.

Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.

Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M.

Clin Cancer Res. 2000 Aug;6(8):3032-7.

9.

Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.

Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T.

Clin Cancer Res. 1999 Jul;5(7):1723-30.

10.

New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus.

Gusella M, Ferrazzi E, Ferrari M, Padrini R.

Ther Drug Monit. 2002 Jun;24(3):425-31.

PMID:
12021636
12.

5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.

Kralovánszky J, Katona C, Jeney A, Pandi E, Noordhuis P, Erdélyi-Tóth V, Otvös L, Kovács P, Van der Wilt CL, Peters GJ.

J Cancer Res Clin Oncol. 1999 Dec;125(12):675-84.

PMID:
10592100
13.

A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.

Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, Allegrini G, Falcone A, Del Tacca M, Danesi R.

Clin Pharmacol Ther. 2006 Oct;80(4):384-95.

PMID:
17015056
14.

Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.

Oman M, Lundqvist S, Gustavsson B, Hafström LO, Naredi P.

Cancer Chemother Pharmacol. 2005 Dec;56(6):603-9. Epub 2005 Jul 27.

PMID:
16047145
15.
16.

[Peripheral 5-FU blood concentration after high-dose injection into the hepatic artery: potential preventive effect on extrahepatic metastatic foci].

Yamamoto Y, Kakisaka A, Minami M, Goto J, Ohara K, Isizaki A, Kino S, Kono T, Kasai S.

Gan To Kagaku Ryoho. 1999 Jul;26(8):1159-62. Japanese.

PMID:
10431582
17.

Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.

Di Paolo A, Ibrahim T, Danesi R, Maltoni M, Vannozzi F, Flamini E, Zoli W, Amadori D, Del Tacca M.

Ther Drug Monit. 2002 Oct;24(5):588-93.

PMID:
12352929
18.

Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.

Cho HK, Lee ES, Lee JW, Park JK, Kang JH, Lee KS, Shim CK, Chung SJ, Kim DD, Kuh HJ.

J Cancer Res Clin Oncol. 2006 May;132(5):320-6. Epub 2006 Jan 4.

PMID:
16395593
20.

A retrospective comparison of concurrent bolus 5-fluorouracil or raltitrexed in preoperative chemoradiation for locally advanced rectal cancer.

Yoney A, Askaroglu B, Hancilar T, Isikli L, Unsal M.

Hematol Oncol Stem Cell Ther. 2008 Jan-Mar;1(1):28-33.

PMID:
20063525

Supplemental Content

Support Center